In AML, mutations in key genes, such as TP53, FLT3, NRAS, KMT2A and PTEN, are frequently observed and are often associated with poor prognosis, therapeutic resistance and distinct molecular profiles, which complicate disease management (36). This evidence concerns the gene TP53 and acute myeloid leukemia.